XFOR
X4 Pharmaceuticals, Inc. Common Stock
stockNASDAQ
x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4's most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.02 | 2026-09-28 | -6.30% | 1.871 |
| 1M | 4.04 | 2026-09-04 | -30.07% | 1.851 |
| 3M | 4.03 | 2026-07-06 | -29.90% | 1.366 |
| 6M | 4.07 | 2026-04-06 | -30.59% | 1.871 |
| 1Y | 3.37 | 2025-10-06 | -16.17% | 1.648 |
| 2Y | 18.64 | 2024-10-04 | -84.84% | — |
| 5Y | 158.10 | 2021-10-05 | -98.21% | 1.309 |
X4 Pharmaceuticals, Inc. Common Stock (NASDAQ:XFOR) stock price today is $2.83, and today's volume is 911,405. XFOR is down 0.177% today. The 30 day average volume is 1.03M. XFOR market cap is $280.09M with 99.15M shares outstanding.